The main objective of the BioPrintIA project is the industrial research of a new treatment based on the generation of new cellularised, functionalised and personalised bio-implants using innovative elements such as artificial intelligence and 3D bio-printing that allow the transplantation of osteo-articular tissues in the injured area to provide a sustainable response to current degenerative knee pathologies derived from ageing and which will represent an innovative treatment to improve the quality of life of patients, thereby reducing the degree of dependence and contributing to the reduction of healthcare costs derived from current treatments.


Generating 3D implants specific to articular cartilage and tendon injuries by developing innovative bio-inks and the corresponding 3D bioprinting system.

Promoting osteoarticular regeneration and the resolution of inflammation and pain through the development of personalised and tissue-specific therapeutic strategies based on stem cell transplantation.

Validating in vitro the bio-inks and their components using a novel organ-on-a-chip model of cartilage and tendon, and in vivo the developed 3D implants through animal models

Validate the 3D implants developed by analysing the results of in vitro and in vivo tests with artificial intelligence.


The solution to be developed consisted of 3D cellularised and functionalised implants with formulas for tissue regeneration and the treatment of osteo-articular degenerative processes, which will provide solutions for clinical needs not met by the currently existing surgical and non-surgical treatments.

Participating entities

Funding Entity

  • Centre for the Development of Industrial Technology


  • Izertis (coordinator)
  • Readycell
  • Solutex
  • Artifical Nature
  • Juncà Gelatines
  • Tecbiocel
  • Carinsa


  • Leitat Foundation
  • Idonial Foundation